Genelux Corp

GNLX11 Dec 2024
Healthcare
$2.73
0.00 (-0.37%)
Lowest Today
$2.66
Highest Today
$2.8
Today’s Open
$2.73
Prev. Close
$2.73
52 Week High
$16.6
52 Week Low
$1.6
To Invest in Genelux Corp

Genelux Corp

Healthcare
GNLX11 Dec 2024
0.00 (-0.37%)
1M
3M
6M
1Y
5Y
Low
$2.66
Day’s Range
High
$2.8
2.66
52 Week Low
$1.6
52-Week Range
52 Week High
$16.6
1.6
1 Day
-
1 Week
-3.87%
1 month return
-9%
3 month return
+5.81%
6 month return
+10.52%
1 Year return
-78.05%
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
94.29 mln
PB Ratio
2.83
PE Ratio
0
Enterprise Value
61.58 mln
Total Assets
27.89 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Organisation
Genelux Corp
Employees
24
Industry
Biotechnology
CEO
Mr. Thomas  Zindrick J.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step